FI102381B1 - Syntetiska polypeptider, som hänför sig till Epstein-Barr-virusets nukleära antigen och förfarande för att identifiera anti-EBNA-antikroppar i ett vävnadsprov - Google Patents

Syntetiska polypeptider, som hänför sig till Epstein-Barr-virusets nukleära antigen och förfarande för att identifiera anti-EBNA-antikroppar i ett vävnadsprov

Info

Publication number
FI102381B1
FI102381B1 FI910587A FI910587A FI102381B1 FI 102381 B1 FI102381 B1 FI 102381B1 FI 910587 A FI910587 A FI 910587A FI 910587 A FI910587 A FI 910587A FI 102381 B1 FI102381 B1 FI 102381B1
Authority
FI
Finland
Prior art keywords
ebna
epstein
barr virus
nuclear antigen
antibodies
Prior art date
Application number
FI910587A
Other languages
English (en)
Finnish (fi)
Other versions
FI910587A0 (fi
FI102381B (sv
Inventor
Gary Rhodes
Richard S Smith
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of FI910587A0 publication Critical patent/FI910587A0/fi
Application granted granted Critical
Publication of FI102381B1 publication Critical patent/FI102381B1/sv
Publication of FI102381B publication Critical patent/FI102381B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6081Albumin; Keyhole limpet haemocyanin [KLH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16211Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16211Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI910587A 1988-08-09 1991-02-07 Syntetiska polypeptider, som hänför sig till Epstein-Barr-virusets nuk leära antigen och förfarande för att identifiera anti-EBNA-antikroppar i ett vävnadsprov FI102381B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/230,250 US5717065A (en) 1984-08-08 1988-08-09 Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen
US23025088 1988-08-09
PCT/US1989/003350 WO1990001495A1 (en) 1988-08-08 1989-08-03 Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen
US8903350 1989-08-03

Publications (3)

Publication Number Publication Date
FI910587A0 FI910587A0 (fi) 1991-02-07
FI102381B1 true FI102381B1 (sv) 1998-11-30
FI102381B FI102381B (sv) 1998-11-30

Family

ID=22864499

Family Applications (1)

Application Number Title Priority Date Filing Date
FI910587A FI102381B (sv) 1988-08-09 1991-02-07 Syntetiska polypeptider, som hänför sig till Epstein-Barr-virusets nuk leära antigen och förfarande för att identifiera anti-EBNA-antikroppar i ett vävnadsprov

Country Status (13)

Country Link
US (1) US5717065A (sv)
EP (1) EP0428629B1 (sv)
AT (1) ATE134648T1 (sv)
AU (1) AU643188B2 (sv)
CA (1) CA1340446C (sv)
DE (1) DE68925819T2 (sv)
DK (1) DK175828B1 (sv)
ES (1) ES2018909A6 (sv)
FI (1) FI102381B (sv)
GR (1) GR890100501A (sv)
NO (1) NO309720B1 (sv)
PT (1) PT91397B (sv)
WO (1) WO1990001495A1 (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008224A1 (en) * 1989-11-24 1991-06-13 The Council Of The Queensland Institute Of Medical Research Im peptides
JPH04310861A (ja) * 1991-04-09 1992-11-02 Kazuo Yanagi 抗ebna抗体の測定方法および抗ebna抗体測定キット
AU667745B2 (en) * 1992-09-14 1996-04-04 Akzo Nobel N.V. Epstein-barr virus peptides and antibodies against these peptides
US5833991A (en) * 1995-04-10 1998-11-10 Cobra Therapeutics, Ltd. Glycine-containing sequences conferring invisibility to the immune system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686282A (en) * 1983-08-12 1987-08-11 Immunetech, Inc. Immunotherapeutic polypeptide agents which block immune complex binding to immunoglobulin Fc receptors
US4654419A (en) * 1984-08-08 1987-03-31 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen
US5116725A (en) * 1984-08-08 1992-05-26 Scripps Clinic And Research Foundation Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides
ZA846192B (en) * 1984-08-09 1986-03-26 Merck Patent Gmbh Immunotherapeutic polypeptide agents

Also Published As

Publication number Publication date
WO1990001495A1 (en) 1990-02-22
EP0428629B1 (en) 1996-02-28
ES2018909A6 (es) 1991-05-16
US5717065A (en) 1998-02-10
DK175828B1 (da) 2005-03-14
DE68925819D1 (de) 1996-04-04
AU4400089A (en) 1990-03-05
EP0428629A1 (en) 1991-05-29
ATE134648T1 (de) 1996-03-15
GR890100501A (el) 1991-12-30
CA1340446C (en) 1999-03-16
DE68925819T2 (de) 1996-10-02
DK21191D0 (da) 1991-02-07
NO309720B1 (no) 2001-03-19
DK21191A (da) 1991-04-04
NO910479L (no) 1991-04-05
PT91397B (pt) 1995-05-04
FI910587A0 (fi) 1991-02-07
AU643188B2 (en) 1993-11-11
FI102381B (sv) 1998-11-30
NO910479D0 (no) 1991-02-07
EP0428629A4 (en) 1991-12-27
PT91397A (pt) 1990-03-08

Similar Documents

Publication Publication Date Title
HU9202645D0 (en) Synthetic antigenes applicables for detecting antibodies of hepatitis c virus
DK532284A (da) Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser
FI20021626A (sv) Reagens för immunoassay och förfarande för detektering av hepatit C-virus (HCV) antikroppar
NZ219113A (en) Hiv peptide containing epitope of the env protein
ES545971A0 (es) Un metodo para analizar los anticuerpos anti-ebna en una muestra corporal.
ES2082775T3 (es) Anticuerpos de proteinas latentes de papilomavirus humano, sistemas de diagnostico y procedimientos.
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
DE69033080D1 (de) Zuwachsfaktorrezeptorgen deriviert von platten des typs oc
FI102381B1 (sv) Syntetiska polypeptider, som hänför sig till Epstein-Barr-virusets nukleära antigen och förfarande för att identifiera anti-EBNA-antikroppar i ett vävnadsprov
DE59610867D1 (de) Rekombinante autologe Fusionsproteine des Epstein-Barr-Virus, diese enthaltende Testkits und Verfahren zum Nachweis von Epstein-Barr-Virus-spezifischen Antikörpern
SG145521A1 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus